| 研究課題/領域番号 |
23K24566
|
|---|
| 補助金の研究課題番号 |
22H03308 (2022-2023)
|
|---|
| 研究種目 |
基盤研究(B)
|
| 配分区分 | 基金 (2024)
補助金 (2022-2023) |
|---|
| 応募区分 | 一般 |
|---|
| 審査区分 |
小区分58010:医療管理学および医療系社会学関連
|
|---|
| 研究機関 | 一橋大学 |
|---|
研究代表者 |
Rahman Mizanur 一橋大学, 社会科学高等研究院, 准教授 (10726433)
|
|---|
| 研究分担者 |
中村 良太 一橋大学, 社会科学高等研究院, 教授 (00717209)
佐藤 主光 一橋大学, 社会科学高等研究院, 教授 (50313458)
ALAM MD・ASHRAFUL 東京大学, 医学部附属病院, 特任研究員 (80866632)
|
|---|
| 研究期間 (年度) |
2022-04-01 – 2025-03-31
|
| 研究課題ステータス |
交付 (2024年度)
|
| 配分額 *注記 |
17,030千円 (直接経費: 13,100千円、間接経費: 3,930千円)
2024年度: 1,430千円 (直接経費: 1,100千円、間接経費: 330千円)
2023年度: 6,630千円 (直接経費: 5,100千円、間接経費: 1,530千円)
2022年度: 8,970千円 (直接経費: 6,900千円、間接経費: 2,070千円)
|
|---|
| キーワード | Hypertension control / Community pharmacy / Quality of life / Cost-effectiveness / Blood pressure / Pharmacy / Bangladesh / Pakistan / India / Health promotion / Treatment adherence / Cluster RCT / blood pressure / quality of life / pharmacy / hypertension |
|---|
| 研究開始時の研究の概要 |
Our study evaluates the impact of pharmacy-based health promotion on hypertensive patients in resource-limited areas by using a cluster-randomized trial. There are 3,600 hypertensive adults in Bangladesh and 360 in Pakistan participating. Phases include baseline surveys with interventions, midline surveys with interventions and follow-ups, and endline surveys with impact evaluations. Two intervention groups will provide community pharmacies with educational training, counseling, phone calls, and text messages. Blood pressure, quality of life, and cost-effectiveness will also be measured.
|
| 研究実績の概要 |
Community pharmacies provided educational training, counseling, phone calls, and text messages in 2023. We analyzed 3600 individual data collected in 2022 in a descriptive manner in 2023. As part of the study protocol, intervention groups receive text messages and phone calls every three months throughout 2023. These calls and messages remind participants to stay healthy and take medications on time. Using the same baseline questionnaire, we conducted a follow-up survey at the end of 2023 to collect sociodemographic information, blood pressure, glucose levels, anthropometric measurements, and self-reports. 96% of respondents responded to the follow-up survey. Based on the contents of the baseline intervention, the pharmacist proposed a second intervention in 2023. A number of meetings have taken place with Prof. Nakamura, Prof. Sato, and Dr. Alam to discuss the follow-up intervention, follow-up survey schedule, and project progress.There were essential contributions made by the Co-Investigators to the research plan, leading to its refinement and preventing any extra costs from being incurred. A manuscript has been submitted to Trials journal for publication following meticulous drafting by the Principal Investigator and significant revision by the Co-Investigators. Following data collection and cleaning, we are currently analyzing 3,600 hypertensive adults from each country in a cluster-randomized trial. The Principal Investigator shared three manuscript preparation plans with Co-Investigators based on baseline survey data.
|
| 現在までの達成度 (区分) |
現在までの達成度 (区分)
1: 当初の計画以上に進展している
理由
Our team of collaborators and dedicated researchers put in commendable effort to collect invaluable data, implement effective interventions, and maintain close collaboration with local pharmacists. This process is proceeding ahead of schedule without any unforeseen incidents at both the baseline and midterm levels of data collection.
|
| 今後の研究の推進方策 |
During 2024, our primary focus will be on conducting a comprehensive analysis of the collected data. Our aim is to investigate the impact of the intervention on both blood pressure levels and overall quality of life. We will then collaborate with our Co-Investigators to review and incorporate their feedback into the analysis. From May to December, our team plans to prepare three manuscripts, each addressing different aspects of the research findings such as interpretation, implications, and recommendations. These manuscripts will be submitted to reputable journals and conferences within the field. Additionally, we have scheduled presentations of our findings at both national and international conferences, specifically the Japan Epidemiological Association's conference in February 2025 and an international conference to be announced. Lastly, the Principal Investigator (PI) has a monitoring trip to Bangladesh planned for the end of 2024 to ensure the smooth progress of the project.
|
